| First Author | Semënov M | Year | 2005 |
| Journal | J Biol Chem | Volume | 280 |
| Issue | 29 | Pages | 26770-5 |
| PubMed ID | 15908424 | Mgi Jnum | J:164786 |
| Mgi Id | MGI:4835150 | Doi | 10.1074/jbc.M504308200 |
| Citation | Semenov M, et al. (2005) SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 280(29):26770-5 |
| abstractText | Sclerosteosis is an autosomal recessive disease that is characterized by overgrowth of bone tissue and is linked to mutations in the gene encoding the secreted protein SOST. Sclerosteosis shares remarkable similarities with 'high bone mass' diseases caused by 'gain-of-function' mutations in the LRP5 gene, which encodes a coreceptor for Wnt signaling proteins. We show here that SOST antagonizes Wnt signaling in Xenopus embryos and mammalian cells by binding to the extracellular domain of the Wnt coreceptors LRP5 and LRP6 and disrupting Wnt-induced Frizzled-LRP complex formation. Our findings suggest that SOST is an antagonist for Wnt signaling and that the loss of SOST function likely leads to the hyperactivation of Wnt signaling that underlies bone overgrowth seen in sclerosteosis patients. |
